ReviewNeurobiology of disease2014
Neuroprotective effects of leptin in the context of obesity and metabolic disorders.
Review in Neurobiology of disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Altered leptin level in autism spectrum disorder and meta-analysis of adipokines.BMC psychiatry · 2024Pooled it
- Leptin: role over central nervous system in epilepsy.BMC neuroscience · 2018Pooled it
- Systematic analysis of associations between obesity and memory decline.GeroScience · 2026Article
- Therapeutic Potential of Leptin in Neurodegenerative Disease.Biomedicines · 2025Review
- Neurobiological and Microbiota Alterations After Bariatric Surgery: Implications for Hunger, Appetite, Taste, and Long-Term Metabolic Health.Brain sciences · 2025Review
- Body Weight Variability and Risk of Suicide Mortality: A Nationwide Population-Based Study.Depression and anxiety · 2024Article
- Association of late-life body mass index with the risk of Alzheimer disease: a 10-year nationwide population-based cohort study.Scientific reports · 2022Article
- Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline.International journal of molecular sciences · 2022Review
- Obesity as a Risk Factor for Dementia and Alzheimer's Disease: The Role of Leptin.International journal of molecular sciences · 2022Review
- Adipokines as Immune Cell Modulators in Multiple Sclerosis.International journal of molecular sciences · 2021Review
- Metabolic Dysfunction in Spinal Muscular Atrophy.International journal of molecular sciences · 2021Review
- The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Polymethoxyselenoflavones exert anti-obesity effects through activation of lipolysis and brown adipocyte metabolism.International journal of obesity (2005) · 2021Article
- Do Leptin Play a Role in Metabolism-Related Psychopathological Symptoms?Frontiers in psychiatry · 2021Article
- The Relationship Between Food Craving, Appetite-Related Hormones and Clinical Parameters in Bipolar Disorder.Nutrients · 2020Article
- Association Between Leptin, Cognition, and Structural Brain Measures Among "Early" Middle-Aged Adults: Results from the Framingham Heart Study Third Generation Cohort.Journal of Alzheimer's disease : JAD · 2020Article
- Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.BMC endocrine disorders · 2019Article
- Effects of Metformin Treatment on Soluble Leptin Receptor Levels in Women with Polycystic Ovary Syndrome.Current medical science · 2019Article
- Hydrogen Sulfide Inhibits Formaldehyde-Induced Senescence in HT-22 Cells via Upregulation of Leptin Signaling.Neuromolecular medicine · 2019Article
- Protective effects of leptin against cerebral ischemia/reperfusion injury.Experimental and therapeutic medicine · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
As the population of the world ages, the prevalence of neurodegenerative disease continues to rise, accompanied by increases in disease burden related to obesity and metabolic disorders. Thus, it will be essential to develop tools for preventing and slowing the progression of these major disease entities. Epidemiologic studies have shown strong associations between obesity, metabolic dysfunction, and neurodegeneration, while animal models have provided insights into the complex relationships between these conditions. Experimentally, the fat-derived hormone leptin has been shown to act as a neuroprotective agent in various animal models of dementia, toxic insults, ischemia/reperfusion, and other neurodegenerative processes. Specifically, leptin minimizes neuronal damage induced by neurotoxins and pro-apoptotic conditions. Leptin has also demonstrated considerable promise in animal models of obesity and metabolic disorders via modulation of glucose homeostasis and energy intake. However, since obesity is known to induce leptin resistance, we hypothesize that resistance to the neuroprotective effects of leptin contributes to the pathogenesis of obesity-associated neurodegenerative diseases. This review aims to explore the literature pertinent to the role of leptin in the protection of neurons from the toxic effects of aging, obesity and metabolic disorders, to investigate the physiological state of leptin resistance and its causes, and to consider how leptin might be employed therapeutically in the prevention and treatment of neurodegenerative disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.